Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    

| More

Maintain ADD on Lupin - Margin recovery holds the key - HDFC Securities

Posted On: 2020-06-01 14:12:39

Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities.

Lupin (Q4FY20 Results Review): Margin recovery holds the key. Maintain ADD

Lupin reported steady revenues led by good traction in India, US and API business. While margins improved (13.7%, +228bps QoQ, lower R&D spends) and recovered from Q3 lows, they still remain subdued and below our expectations. Lupin has been guiding towards an improving cost structure, however, benefits of those are yet to be seen. Going forward, we factor significant gains from operating leverage to aid margin expansion driven by key launches viz. gProAir, Levothyroxine ramp up and several cost containment measures (stable R&D, lower SG&A spends, savings on Solosec). With improving profitability and moderate capex (slightly higher than Rs5bn), we expect FCF generation of ~Rs40bn over FY20-22e. We raise our earnings by 12-18% for FY21/22 to factor slightly higher margins, lower depreciation and tax rate. Revise TP to Rs920 based on 21x FY22 EPS.

Q4 snapshot - Revenues at Rs38.4bn (flat YoY, +2% QoQ, gRanexa exclusivity in the base) were driven by healthy growth in India (+13% YoY), API (+13% YoY) and US biz (USD212mn, up 14% QoQ, stable base, ramp up in Levo, some stock piling). EBIDTA Margins improved by 228bps QoQ largely on account of lower R&D (-240bps QoQ) & other exp (- 55bps QoQ).

gProAir approval and ramp up in Levothyroxine critical for US growth: Lupin has a rich pipeline for the US (158 pending ANDAs, 43 FTFs); however, in the near term, scale up in Levothyroxine (market share ramp up from 13% in Q4 to ~20% in FY21), ramp up in recent launches, gProAir approval (before 2HFY21) will be the key growth drivers. We expect softer trends in Solosec in FY21, although net pricing is likely to improve.

Multiple levers for margin expansion in place: We expect good growth in key markets, high value launches in US coupled with several cost containment measures such as better procurement, lower SG&A spends, reduction in Solosec burn rate (annual savings of USD25mn), stable R&D exp to drive ~500bps margin expansion over the next two years.

Key call takeaways: a) Guidance for FY21- EBIDTA margin of 19-20% incl other income, R&D cost - Rs15bn (flat YoY), capex - slightly higher than Rs5bn, tax rate - 35%, to further reduce in FY22; Q1FY21- to be softer; b) Key products - gProAir approval (before 2HFY21), gFostair approval in EU by next qtr, launch by end of FY21, Peg-filgrastim filing in US by end of FY21, gSpiriva in US - TA in FY21,launch in 2022; c) Plant remediation timeline - to invite FDA for reinspection in next 2 months for Goa followed by Indore, Somerset to precede Goa; d) Metformin NDMA issue - to recall one batch; e) Net debt - Rs15.1bn. Reduced further by ~USD267mn post March.

Maintain Add, risks: We increase our TP to Rs920 based on 21x FY22e EPS. Key risks: delay in resolution of key plants, delay in key approvals, higher price erosion in the US, adverse outcome on drug price-fixing lawsuit in the US, escalation of NDMA issue in Metformin.

Shares of LUPIN LTD. was last trading in BSE at Rs.869.8 as compared to the previous close of Rs. 881.45. The total number of shares traded during the day was 292657 in over 9185 trades.

The stock hit an intraday high of Rs. 881.5 and intraday low of 840.4. The net turnover during the day was Rs. 251973614.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Real Estate (Sector Update) - Greenshoots visible - HDFC Securities

Cement (Sector Update) - Prices, retail sales hold up despite COVID - HDFC Securities

TCI Express - Branch economics, cost levers as margin tailwinds - ICICI Securities

Mishra Dhatu Nigam - Space order inflow may slow down in FY21 - ICICI Securities

Century Plyboards - Compelling BUY; top pick in building materials - ICICI Securities

Building material - Sector Update - ICICI Securities

ISGEC Heavy Engineering - On a strong footing despite macro headwinds - ICICI Securities

Telecom - Growth breaks due to Covid-19 crisis - ICICI Securities

Pfizer Ltd - Company Update - ICICI Securities

Petronet LNG - Quant Pick - ICICI Securities

Earnings Wrap Q4FY20: Quarter end lockdown takes toll, one-offs rule Q4FY20

Autos & Transportation Sector Update Report - Focus on '3Cs' - HDFC Securities

Banking Sector Credit Trends - Weakness building - HDFC Securities

India Equity Strategy Report - Back to pre-covid levels - HDFC Securities

Strategy: Cyclicals to lead earnings recovery over FY20-22 - ICICI Securities

JK Cement - Ripe for re-rating - ICICI Securities

Phillips Carbon Black - Company Update - ICICI Securities

Information Technology - Q1FY21 Result Preview - ICICI Securities

Motherson Sumi Systems Ltd - Company Update - ICICI Securities

HDFC Ltd - Quant Pick - ICICI Securities

Auto Sales Data for June 2020 - Angel Broking

FMCG - Sector Review 4QFY20 - Disruption visible, growth divergence increases - HDFC Securities

Maintain ADD on ONGC - Impairment loss drags earnings - HDFC Securities

Maintain BUY on Ahluwalia Contracts - Looking ahead - HDFC Securities

RIL-Intel Deal - Angel Broking

Strategy: 'Out of turn' change in NIFTY50 due to Vedanta delisting - ICICI Securities

Time Technoplast - Q4FY20 Result Update - ICICI Securities

Monthly Auto Volumes - July 2020 - ICICI Securities

Oil & Natural Gas Corporation - Q4FY20 Result Update - ICICI Securities

Minda Industries - Q4 FY20 Result Update - ICICI Securities

Auto Sales - June 2020 - Acuité Ratings & Research

Bharat Electronics - Q4FY20 Result Update - ICICI Securities

Petronet LNG - Q4FY20 Result Update - ICICI Securities

Tata Steel - Q4FY20 Result Update - ICICI Securities

Phoenix Mills - Q4FY20 Result Update - ICICI Securities

Jun-20 Volumes expectations: Sales to rise over 2x from May-20 levels for Hero, Maruti - HDFC Securities

Maintain REDUCE on RBL Bank - Risks more evident - HDFC Securities

Maintain ADD on Subros - Expect market share gains to continue - HDFC Securities

Maintain ADD on Petronet LNG - One offs in opex drag profitability - HDFC Securities

Siyaram Silk Mills - Company Update - ICICI Securities

Vardhman Textiles - Company Update - ICICI Securities

Bharat Forge - Q4FY20 Result Update - ICICI Securities

CESC - Q4FY20 Result Update - ICICI Securities

Star Cement - Company Update - ICICI Securities

BUY on GIC Reinsurance - Arduous Road Ahead - HDFC Securities

ADD on Oil India - Excess provisions drag EBITDA - HDFC Securities

Maintain BUY on Sobha - Well placed for recovery - HDFC Securities

Maintain REDUCE on Emami - Miss on all fronts - HDFC Securities

BUY on Galaxy Surfactants - Higher per unit EBITDA leads profitability - ICICI Securities

Maintain BUY on J. Kumar Infraprojects - Migration headwinds - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019